This study is looking at a potential treatment for Non-alcoholic fatty liver disease. NAFLD is the largest chronic liver disease in the world with the prevalence estimated to be approximately 30% of adults in developed countries such as Australia and the United States.

8 nights
7 visits

There are currently no drugs available for the treatment of NAFLD. It is treated via weight loss, which can be difficult to maintain long-term with lifestyle changes alone. The goal of this medication is to assist in achieving and maintaining that weight loss.

At this phase of testing we are seeking healthy participants who have a BMI between 25 and 40 to assess how the medication is metabolised by the body. The goal at this stage is not to determine if the treatment actually leads to weight loss.

This clinical trial has been approved by an independent ethics committee, and eligible participants will be reimbursed for their time.

Call us on 1800 243 733 to discuss your eligibility today!


Biological Sex Healthy males or females
Age 18 - 59 years old
BMI 25 – 40 kg/m²
Medication Not taking any (contraception, and high cholesterol and high blood pressure medication are permitted)
Medical History Nothing significant
Smoking History Non smokers